Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Operations: 2009-2024

Historic Cash from Operations for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Dec 2024 value amounting to $1.3 billion.

  • UNITED THERAPEUTICS's Cash from Operations rose 49.02% to $562.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 36.92%. This contributed to the annual value of $1.3 billion for FY2024, which is 35.70% up from last year.
  • As of FY2024, UNITED THERAPEUTICS's Cash from Operations stood at $1.3 billion, which was up 35.70% from $978.0 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Cash from Operations ranged from a high of $1.3 billion in FY2024 and a low of $598.2 million during FY2021.
  • For the 3-year period, UNITED THERAPEUTICS's Cash from Operations averaged around $1.0 billion, with its median value being $978.0 million (2023).
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Cash from Operations soared by 465.78% in 2020, and later fell by 20.84% in 2021.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Cash from Operations stood at $755.7 million in 2020, then decreased by 20.84% to $598.2 million in 2021, then skyrocketed by 34.15% to $802.5 million in 2022, then climbed by 21.87% to $978.0 million in 2023, then skyrocketed by 35.70% to $1.3 billion in 2024.